Amgen Inc AMGN
Analyst Ratings
- Consensus
- Hold — 9 Buy · 14 Hold · 2 Sell (25 analysts)
- Avg. Price Target
- $394.96 (+2.4% upside)
Key Stats
- Today's Range
- $378.51 – $386.50
- 50-Day Range
- $353.95 – $447.03
- 52-Week Range
- $269.77 – $447.03
- Volume
- 8.53 million shs
- Average Volume
- 2.72 million shs
- Market Cap
- $205.32 billion
- P/E Ratio
- 23.95
- Dividend Yield
- 2.61%
Valuation
- P/E Ratio
- 23.95
- Price / Book
- 17.57
- Price / Sales
- 5.39
Dividend
- Dividend Yield
- 2.61%
- Annual Dividend
- $10.08
- Payout Ratio
- 62.61%
- Ex-Dividend Date
- 2026-08-21
Short Interest
- Short Interest
- 1.66%
- Days to Cover
- 4.34
Financials (TTM)
- Revenue
- $38.09 billion
- Net Income
- $8.74 billion
- Net Margin
- 22.95%
- Return on Equity
- 74.80%
- Debt-to-Equity
- 4.90
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Related Stocks
Compare head-to-head: AMGN vs MRNA·AMGN vs HALO·AMGN vs TWST·AMGN vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.